If the United States is serious about maintaining its leadership in biopharmaceuticals, then it’s time for policymakers to articulate and embrace a robust sectoral competitiveness strategy.
For brief overviews of how key technologies work and why they matter, see ITIF’s “Technology Explainer Series.”